EDP-938 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus (RSV)
Conditions
Respiratory Syncytial Virus (RSV)
Trial Timeline
Apr 26, 2022 → Aug 19, 2024
NCT ID
NCT04816721About EDP-938 + Placebo
EDP-938 + Placebo is a phase 2 stage product being developed by Enanta Pharmaceuticals for Respiratory Syncytial Virus (RSV). The current trial status is completed. This product is registered under clinical trial identifier NCT04816721. Target conditions include Respiratory Syncytial Virus (RSV).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05568706 | Phase 2 | Completed |
| NCT04816721 | Phase 2 | Completed |
| NCT04633187 | Phase 2 | Terminated |
| NCT04196101 | Phase 2 | Completed |
| NCT03384823 | Phase 1 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus (RSV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 80 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 36 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| YMC026 + Placebo | Yuhan | Approved | 85 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 52 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 77 |
| S-337395 + Placebo | Shionogi | Phase 2 | 52 |
| Sivelestat | Eli Lilly | Phase 1/2 | 41 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 52 |
| Paracetamol 500 mg/Phenylephrine 5 mg tablets + Paracetamol 1000 mg/Phenylephrine 10 mg sachet | Johnson & Johnson | Phase 1 | 33 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1 | 33 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Placebo + AZD5634 | AstraZeneca | Phase 1 | 33 |
| MEDI8897 + Palivizumab | AstraZeneca | Phase 2/3 | 65 |
| Selumetinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Tozorakimab + Placebo | AstraZeneca | Phase 3 | 77 |
| Nirsevimab | AstraZeneca | Phase 3 | 77 |
| Nirsevimab + Placebo | AstraZeneca | Phase 3 | 77 |